Predicting risk reduction of coronary disease in patients who are glucose intolerant: a comparison of treatment with fenofibrate and other lipid-modifying agents.

Managed care interface

Volumn 13, Issue 3, 2000, Pages 52-58

  Haffner, S M ^a   Ashraf, T ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; CLASSIFICATION; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; COST CONTROL; ECONOMICS; GLUCOSE INTOLERANCE; HUMAN; HYPERLIPIDEMIA; RISK FACTOR; TREATMENT OUTCOME; UNITED STATES;

ANTILIPEMIC AGENTS; CORONARY DISEASE; COST SAVINGS; COST-BENEFIT ANALYSIS; GLUCOSE INTOLERANCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; PROCETOFEN; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 0034154629     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)